1. Anttila, A, Pukkala, E, Söderman, B, et al. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963–1995: recent increase in cervical cancer incidence. Int J Cancer 1999; 83: 59–65.
Google Scholar | Crossref | Medline | ISI2. Kyndi, M, Frederiksen, K, Krüger Kjaer, S. Cervical cancer incidence in Denmark over six decades (1943-2002). Acta Obstet Gynecol Scand 2006; 85: 106–111.
Google Scholar | Crossref | Medline | ISI3. Engholm, G, Ferlay, J, Christensen, N, et al. Cancer incidence, mortality, prevalence and survival in the Nordic countries, version 8.1 (28.06.2018). Association of the Nordic Cancer Registries, Danish Cancer Society, Copenhagen, Denmark, 2018.
Google Scholar4. Dillner, J, Andrae, B. Livmoderhalscancer ökar hos kvinnor med normalt cellprov. Lakartidningen 2018; 115: 1–3.
Google Scholar5. Anttila, A, Leivonen, A, Heinävaara, S, et al. Kohdunkaulasyövän seulontaohjelma—Vuosikatsaus 2020 (cervical cancer screening programme in Finland—annual review). Finnish Cancer Registry 2020; 1–20.
Google Scholar6. Lehtinen, M, Lagheden, C, Luostarinen, T, et al. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point – registry-based follow-up of three cohorts from randomized trials. BMJ Open 2017; 7: e015867.
Google Scholar | Crossref | Medline7. Arbyn, M, Ronco, G, Anttila, A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012; 30: F88–F99.
Google Scholar | Crossref | Medline | ISI8. Hall, MT, Simms, KT, Lew, J, Bin, et al. Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017–2035: example from Australia. PLoS One 2018; 13: e0185332–19.
Google Scholar | Crossref | Medline9. Moscicki, A-B, Schiffman, M, Burchell, A, et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 2012; 30: F24–F33.
Google Scholar | Crossref | Medline | ISI10. Cuschieri, K, Ronco, G, Lorincz, A, et al. Eurogin roadmap 2017: triage strategies for the management of HPV-positive women in cervical screening programs. Int J Cancer 2018; 143: 735–745.
Google Scholar | Crossref | Medline11. Anttila, A, Kotaniemi-Talonen, L, Leinonen, M, et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. Bmj 2010; 340: c1804.
Google Scholar | Crossref | Medline12. Partanen, VM, Anttila, A, Heinävaara, S, et al. NordScreen—an interactive tool for presenting cervical cancer screening indicators in the Nordic countries. Acta Oncol 2019; 58: 1199–1204.
Google Scholar | Crossref | Medline13. Partanen, VM, Heinävaara, S, Waldstrøm, M, et al. Adherence to international recommendations in the governance and organisation of Nordic cervical cancer screening programmes. Acta Oncol 2020; 59: 1308–1315.
Google Scholar | Crossref | Medline14. Nationellt Kvalitetsregister för Cervixcancerprevention (NKCx ). Förebyggande av livmoderhalscancer i Sverige—Verksamhetsberättelse och årsrapport 2019 med data till och med 2018. 2019. [Prevention of Cervical Cancer in Sweden—Annual Report 2019 with Data up to 2018] 2019; 1–104.
Google Scholar15. Cancer Registry of Norway. Livmorhalsprogrammet – Årsrapport 2016. [Cervical Program—Annual Report 2016] 2018; 1–44.
Google Scholar16. Arbyn, EM, Anttila, A, Jordan, J, et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. 2nd ed. Luxembourg: Office for Official Publications of the European Communities, 2008.
Google Scholar17. Pedersen, K, Fogelberg, S, Thamsborg, LH, et al. An overview of cervical cancer epidemiology and prevention in Scandinavia. Acta Obstet Gynecol Scand 2018; 97: 795–807.
Google Scholar | Crossref | Medline18. Veijalainen, O, Kares, S, Kujala, P, et al. Human papillomavirus test with cytology triage in organized screening for cervical cancer. Acta Obstet Gynecol Scand 2016; 95: 1220–1227.
Google Scholar | Crossref | Medline19. Machalek, DA, Roberts, JM, Garland, SM, et al. Routine cervical screening by primary HPV testing: early findings in the renewed national cervical screening program. Med J Aust 2019; 211: 113–119.
Google Scholar | Crossref | Medline20. Thomsen, LT, Kjær, SK, Munk, C, et al. Clinical performance of human papillomavirus (HPV) testing versus cytology for cervical cancer screening: results of a large Danish implementation study. Clin Epidemiol 2020; 12: 203–213.
Google Scholar | Crossref | Medline21. Hashim, D, Engesæter, B, Baadstrand Skare, G, et al. Real-world data on cervical cancer risk stratification by cytology and HPV genotype to inform the management of HPV-positive women in routine cervical screening. Br J Cancer 2020; 122: 1715–1723.
Google Scholar | Crossref | Medline22. Gage, JC, Katki, HA, Schiffman, M, et al. Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection. Int J Cancer 2015; 136: 1665–1671.
Google Scholar | Crossref | Medline23. Farnsworth, A, Roberts, JM, Garland, SM, et al. Detection of high-grade cervical disease among women referred directly to colposcopy after a positive HPV screening test varies with age and cytology findings. Int J Cancer 2020; 147: 3068–3074.
Google Scholar | Crossref | Medline